WallStSmart

Kodiak Sciences Inc (KOD)vsModerna Inc (MRNA)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

KOD leads profitability with a 0.0% profit margin vs -141.4%. KOD earns a higher WallStSmart Score of 25/100 (F).

KOD

Avoid

25

out of 100

Grade: F

Growth: 4.3Profit: 3.0Value: 5.0Quality: 4.0
Piotroski: 1/9Altman Z: -7.30

MRNA

Avoid

21

out of 100

Grade: F

Growth: 2.7Profit: 2.0Value: 6.7Quality: 7.5
Piotroski: 3/9Altman Z: 2.09
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for KOD.

MRNAUndervalued (+69.9%)

Margin of Safety

+69.9%

Fair Value

$134.69

Current Price

$194.82

$60.13 discount

UndervaluedFair: $134.69Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

KOD0 strengths · Avg: 0/10

No standout strengths identified

MRNA2 strengths · Avg: 9.0/10
Market CapQuality
$69.04B9/10

Large-cap with strong market position

Debt/EquityHealth
0.199/10

Conservative balance sheet, low leverage

Areas to Watch

KOD4 concerns · Avg: 3.5/10
Revenue GrowthGrowth
0.0%4/10

0.0% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Operating MarginProfitability
0.0%3/10

Operating margin of 0.0%

MRNA4 concerns · Avg: 3.3/10
Price/BookValuation
11.5x4/10

Trading at 11.5x book value

Revenue GrowthGrowth
2.1%4/10

2.1% revenue growth

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Return on EquityProfitability
-46.6%2/10

ROE of -46.6% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : KOD

KOD has a balanced fundamental profile.

Bull Case : MRNA

The strongest argument for MRNA centers on Market Cap, Debt/Equity.

Bear Case : KOD

The primary concerns for KOD are Revenue Growth, EPS Growth, Profit Margin. Debt-to-equity of 1.57 is elevated, increasing financial risk.

Bear Case : MRNA

The primary concerns for MRNA are Price/Book, Revenue Growth, Piotroski F-Score.

Key Dynamics to Monitor

KOD profiles as a value stock while MRNA is a turnaround play — different risk/reward profiles.

KOD carries more volatility with a beta of 2.18 — expect wider price swings.

MRNA is growing revenue faster at 2.1% — sustainability is the question.

KOD generates stronger free cash flow (-47M), providing more financial flexibility.

Bottom Line

KOD scores higher overall (25/100 vs 21/100). MRNA offers better value entry with a 69.9% margin of safety. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Kodiak Sciences Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Kodiak Sciences Inc., a clinical-stage biopharmaceutical company, is dedicated to researching, developing, and marketing therapies to treat retinal diseases in the United States and international markets. The company is headquartered in Palo Alto, California.

Moderna Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts.

Want to dig deeper into these stocks?